Dianthus Therapeutics, Inc.
DNTH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | -$0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 120.6% | -56% | 334.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,627.1% | -1,692.1% | -460.6% | -886.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,362.8% | -1,541.2% | -443.8% | -888.1% |
| EPS Diluted | -2.55 | -8.45 | -7.6 | -3.82 |
| % Growth | 69.8% | -11.2% | -99% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |